Corvus Pharmaceuticals, Inc. Price Chart
Corvus Pharmaceuticals, Inc. C17.F Financial and Trading Overview
| Corvus Pharmaceuticals, Inc. stock price | 1.65 EUR |
| Previous Close | 3.14 EUR |
| Open | 2.24 EUR |
| Bid | 2.26 EUR x 40000 |
| Ask | 2.32 EUR x 40000 |
| Day's Range | 2.24 - 2.24 EUR |
| 52 Week Range | 0.57 - 3.56 EUR |
| Volume | 500 EUR |
| Avg. Volume | 245 EUR |
| Market Cap | 62.48M EUR |
| Beta (5Y Monthly) | 1.068309 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.847 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.13 EUR |
C17.F Valuation Measures
| Enterprise Value | 112.2M EUR |
| Trailing P/E | N/A |
| Forward P/E | -2.488889 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.135367 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.632 |
Trading Information
Corvus Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 1.068309 |
| 52-Week Change | 253.64% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.56 EUR |
| 52 Week Low | 0.57 EUR |
| 50-Day Moving Average | 1.93 EUR |
| 200-Day Moving Average | 1.08 EUR |
C17.F Share Statistics
| Avg. Volume (3 month) | 245 EUR |
| Avg. Daily Volume (10-Days) | 50 EUR |
| Shares Outstanding | 29.28M |
| Float | 32.09M |
| Short Ratio | N/A |
| % Held by Insiders | 3.97% |
| % Held by Institutions | 45.90% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -24.47% |
| Return on Equity (ttm) | -58.99% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -30892000 EUR |
| Net Income Avi to Common (ttm) | -40883000 EUR |
| Diluted EPS (ttm) | -0.847 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 34.47M EUR |
| Total Cash Per Share (mrq) | 0.74 EUR |
| Total Debt (mrq) | 2.3M EUR |
| Total Debt/Equity (mrq) | 4.71 EUR |
| Current Ratio (mrq) | 4.288 |
| Book Value Per Share (mrq) | 1.049 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -28710000 EUR |
| Levered Free Cash Flow (ttm) | -17848124 EUR |
Profile of Corvus Pharmaceuticals, Inc.
| Country | Germany |
| State | CA |
| City | Burlingame |
| Address | 863 Mitten Road |
| ZIP | 94010 |
| Phone | 650 900 4520 |
| Website | https://www.corvuspharma.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 29 |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
Q&A For Corvus Pharmaceuticals, Inc. Stock
What is a current C17.F stock price?
Corvus Pharmaceuticals, Inc. C17.F stock price today per share is 1.65 EUR.
How to purchase Corvus Pharmaceuticals, Inc. stock?
You can buy C17.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Corvus Pharmaceuticals, Inc.?
The stock symbol or ticker of Corvus Pharmaceuticals, Inc. is C17.F.
How many shares does Corvus Pharmaceuticals, Inc. have in circulation?
The max supply of Corvus Pharmaceuticals, Inc. shares is 64.84M.
What is Corvus Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Corvus Pharmaceuticals, Inc. PE Ratio is now.
What was Corvus Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Corvus Pharmaceuticals, Inc. EPS is -0.847 EUR over the trailing 12 months.